Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 15.49 -6.12% -1.01
HALO closed down 6.12 percent on Friday, March 22, 2019, on 1.19 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical HALO trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 21 20 DMA Resistance Bearish -6.12%
Mar 21 50 DMA Support Bullish -6.12%
Mar 21 Spinning Top Other -6.12%
Mar 20 200 DMA Resistance Bearish -6.35%
Mar 20 Bearish Engulfing Bearish -6.35%
Mar 20 Fell Below 20 DMA Bearish -6.35%
Mar 20 Outside Day Range Expansion -6.35%

Older signals for HALO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Solid Tumors Antibodies Diabetes Mellitus Clinical Trial Product Hoffmann La Roche Hyaluronidase
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.54
52 Week Low 13.24
Average Volume 758,069
200-Day Moving Average 16.7498
50-Day Moving Average 16.405
20-Day Moving Average 16.52
10-Day Moving Average 16.175
Average True Range 0.5424
ADX 19.15
+DI 17.8244
-DI 31.0815
Chandelier Exit (Long, 3 ATRs ) 16.1328
Chandelier Exit (Short, 3 ATRs ) 16.9272
Upper Bollinger Band 17.8466
Lower Bollinger Band 15.1934
Percent B (%b) 0.11
BandWidth 16.060533
MACD Line -0.0938
MACD Signal Line -0.0366
MACD Histogram -0.0572
Fundamentals Value
Market Cap 2.07 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -16.66
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.87
Resistance 3 (R3) 17.02 16.72 16.64
Resistance 2 (R2) 16.72 16.37 16.64 16.56
Resistance 1 (R1) 16.10 16.15 15.95 15.95 16.49
Pivot Point 15.80 15.80 15.72 15.72 15.80
Support 1 (S1) 15.18 15.45 15.03 15.03 14.49
Support 2 (S2) 14.88 15.23 14.80 14.42
Support 3 (S3) 14.26 14.88 14.34
Support 4 (S4) 14.11